RxSight
RXST· Manufacturing· Fiscal year ends in December
CEO pay in FY2025Stock -69.7% in FY2025
Ron Kurtz, M.D. is the CEO of RxSight and was paid $4.7M in FY2025 (Dec), down 33%.
Pay$100 in the stock at the end of FY21 → $93
Executives5
See all- 1Ron Kurtz, M.D.Chief Executive Officer, President and DirectorFY2025
- 2Eric WeinbergChief Business Development OfficerFY2025
- 3Shelley ThunenFormer Chief Financial OfficerFY2025
- 4Ilya Goldshleger, Ph.D.Chief Operating OfficerFY2025
- 5Scott GainesChief Customer OfficerFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allRxSight paid its 5 named executives $14.6M in total in FY2025 (Dec). CEO Ron Kurtz, M.D. was paid $4.7M of that.
| Name | |||
|---|---|---|---|
| Ron Kurtz, M.D.Chief Executive Officer, President and Director | |||
| Eric WeinbergChief Business Development Officer | |||
| Shelley ThunenFormer Chief Financial Officer | |||
| Ilya Goldshleger, Ph.D.Chief Operating Officer | |||
| Scott GainesChief Customer Officer | Not disclosed | Not disclosed |
of each named executive, from the Summary Compensation Table of each proxy.
Peers19
See all
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.
Board3
See all- Julie B. AndrewsDirector · 4 yr on the boardIndependentAudit (Chair)—Paid as an executive
- Shweta Singh ManiarDirector · 4 yr on the boardIndependentGovernance—Paid as an executive
- Tamara Fountain, M.D.Director · 3 yr on the boardIndependentAudit—Paid as an executive
The board of the latest proxy (FY2025).
Activity
Filings6
See all| Proxy statement | DEF 14A | Apr 28, 2026 | FY2025 |
| Annual report | 10-K | Feb 25, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 21, 2025 | FY2024 |
| Annual report | 10-K | Feb 25, 2025 | FY2024 |
| Proxy statement | DEF 14A | Apr 25, 2024 | FY2023 |
| Annual report | 10-K | Feb 28, 2024 | FY2023 |
